184 related articles for article (PubMed ID: 15319627)
1. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
[TBL] [Abstract][Full Text] [Related]
2. Use of infliximab in pediatric patients with inflammatory bowel disease.
Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
[TBL] [Abstract][Full Text] [Related]
3. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
[TBL] [Abstract][Full Text] [Related]
4. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
5. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
6. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
Stephens MC; Shepanski MA; Mamula P; Markowitz JE; Brown KA; Baldassano RN
Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
[TBL] [Abstract][Full Text] [Related]
8. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
Crandall WV; Mackner LM
Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
[TBL] [Abstract][Full Text] [Related]
9. A home infliximab infusion program.
Condino AA; Fidanza S; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in pediatric ulcerative colitis: two-year follow-up.
Mamula P; Markowitz JE; Cohen LJ; von Allmen D; Baldassano RN
J Pediatr Gastroenterol Nutr; 2004 Mar; 38(3):298-301. PubMed ID: 15076630
[TBL] [Abstract][Full Text] [Related]
12. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.
Falaiye TO; Mitchell KR; Lu Z; Saville BR; Horst SN; Moulton DE; Schwartz DA; Wilson KT; Rosen MJ
J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):213-9. PubMed ID: 24048170
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
14. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
15. Infliximab as a novel therapy for pediatric ulcerative colitis.
Mamula P; Markowitz JE; Brown KA; Hurd LB; Piccoli DA; Baldassano RN
J Pediatr Gastroenterol Nutr; 2002 Mar; 34(3):307-11. PubMed ID: 11964959
[TBL] [Abstract][Full Text] [Related]
16. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
[TBL] [Abstract][Full Text] [Related]
18. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
[TBL] [Abstract][Full Text] [Related]
20. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
